Expertise in
63
conditions

Dr. Rama Balaraman

Hematology | Oncology
3130 SW 32nd Ave, 
Ocala, FL 
On Staff At
Accepting New Patients
Expertise in
63
conditions
3130 SW 32nd Ave, 
Ocala, FL 

Overview

Rama Balaraman is a Hematologist and an Oncologist in Ocala, Florida. Dr. Balaraman is highly rated in 63 conditions, according to our data. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Breast Cancer. Dr. Balaraman is currently accepting new patients.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Thanjavur Med College-Univ Of Madras

Residency

St. Mary's Health Center , Internal Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in FL

Board Certifications

American Board Of Internal Medicine

Fellowships

University of Missouri-Columbia , Internal Medicine

Hospital Affiliations

HCA Florida Ocala Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Dominion National
  • MEDICARE PDP
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Florida Cancer Affiliates
3130 SW 32nd Ave, Ocala, FL 34474
Other Locations
Florida Cancer Affiliates
13940 N US Highway 441 Ste 203, Lady Lake, FL 32159
Florida Cancer Affiliates
9401 SW Highway 200 Ste 702, Ocala, FL 34481

Additional Areas of Focus

Dr. Balaraman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Drug
Study Drugs: BT8009, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

3 Total Publications

600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 25, 2025
Similar Doctors
Expertise in
7
conditions
Dr. Thomas George
Hematology | Oncology
Expertise in
7
conditions
Dr. Thomas George
Hematology | Oncology

UF Health Gastrointestinal (Gi) Oncology Center

1600 SW Archer Rd Rm D2-3, 
Gainesville, FL 
 (40.9 miles away)
352-265-0535
Languages Spoken:
English
See accepted insurances

Thomas George is a Hematologist and an Oncologist in Gainesville, Florida. Dr. George is highly rated in 7 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Colonoscopy.

Expertise in
72
conditions
Dr. Maen A. Hussein
Hematology | Oncology
Expertise in
72
conditions
Dr. Maen A. Hussein
Hematology | Oncology

Florida Cancer Spcialists PLLC

2955 Brownwood Blvd Ste 107, 
The Villages, FL 
 (21.2 miles away)
352-765-7100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Maen Hussein is a Hematologist and an Oncologist in The Villages, Florida. Dr. Hussein is highly rated in 72 conditions, according to our data. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Colorectal Cancer, and Myelodysplastic Syndrome (MDS). Dr. Hussein is currently accepting new patients.

Expertise in
17
conditions
Dr. James Lynch
Hematology | Oncology
Expertise in
17
conditions
Dr. James Lynch
Hematology | Oncology

Uf Health Medical Oncology-Davis Cancer Pavilion

1535 Gale Lemerand Dr, 
Gainesville, FL 
 (40.9 miles away)
352-265-0725
Languages Spoken:
English
See accepted insurances

James Lynch is a Hematologist and an Oncologist in Gainesville, Florida. Dr. Lynch is highly rated in 17 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Gastric Lymphoma, Large-Cell Immunoblastic Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).

Frequently Asked Questions about Dr. Rama Balaraman

How do I make an appointment with Dr. Rama Balaraman?

You can book an appointment with Dr. Rama Balaraman by calling their office at 352-732-4032. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rama Balaraman a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rama Balaraman is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rama Balaraman specialize in?

While Dr. Rama Balaraman is a Hematology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rama Balaraman participate in research or clinical trials?

Yes. Dr. Rama Balaraman has published 3 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Rama Balaraman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rama Balaraman accept my insurance?

Dr. Rama Balaraman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 352-732-4032 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Balaraman's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 52 Advanced Conditions
    View All 120 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile